Announcements
Sidley Represents Neomorph in Its US$100 Million Series B Financing
April 15, 2026
Sidley represented Neomorph, Inc., a biotechnology company developing innovative molecular glue degraders, in its US$100 million Series B financing. The round was led by Deerfield Management, with participation from new investors Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, and Binney Street Capital. The proceeds from the financing will support Neomorph’s continued advancement of its proprietary platform and pipeline focused on discovering and developing molecular glue degraders targeting previously intractable diseases.
The Sidley team was led by Rosemary G. Reilly (Emerging Companies and Venture Capital) and included Rebecca Nauta (Emerging Companies and Venture Capital) and Matthew Dutton (Investment Funds).
連絡先
得意分野
Suggested News & Insights
Sidley Represents GE HealthCare in Its US$945 Million Acquisition of SOFIE BiosciencesOctober 7, 2026Sidley Represents Jiangsu Nhwa Pharmaceutical in Its US$517.5 Million Licensing Transaction With SomniveraSeptember 30, 2026Sidley Represents Bluevine in Its US$340 Million Acquisition by Valley National BankSeptember 28, 2026Sidley Represents Star51 Capital in Its Investment in UltraSight’s US$24 Million FinancingSeptember 25, 2026Sidley Represents Cymphony in Its US$30 Million Series A FinancingSeptember 18, 2026When the Meeting Minutes and the AI Transcript Don’t Match: Litigation Insights From Delaware ChancerySeptember 17, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory


